Fiber laser manufacturer IPG Photonics (NASDAQ:IPGP) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, but sales fell by 9.6% year on year to $227.8 million. On the other hand, next quarter’s revenue guidance of $225 million was less impressive, coming in 1.3% below analysts’ estimates. Its non-GAAP profit of $0.34 per share was 56.3% above analysts’ consensus estimates.
Revenue: $227.8 million vs analyst estimates of $225.1 million (9.6% year-on-year decline, 1.2% beat)
Adjusted EPS: $0.34 vs analyst estimates of $0.22 (56.3% beat)
Adjusted EBITDA: $17.17 million vs analyst estimates of $23.42 million (7.5% margin, 26.7% miss)
Revenue Guidance for Q2 CY2025 is $225 million at the midpoint, below analyst estimates of $227.9 million
Adjusted EPS guidance for Q2 CY2025 is $0.10 at the midpoint, below analyst estimates of $0.33
EBITDA guidance for Q2 CY2025 is $23.5 million at the midpoint, below analyst estimates of $28.07 million
Operating Margin: 0.8%, down from 7.6% in the same quarter last year
Free Cash Flow was -$11.37 million, down from $26.54 million in the same quarter last year
Inventory Days Outstanding: 190, up from 180 in the previous quarter
Market Capitalization: $2.83 billion
StockStory’s Take
IPG Photonics’ first quarter was driven by stabilization in core markets and initial success in newer applications such as medical lasers and micromachining. CEO Dr. Mark Gitin noted, “Bookings improved sequentially and book-to-bill was the strongest we’ve seen in more than two years,” citing growth in e-mobility applications in China, medical customer wins, and the cleanLASER acquisition as contributors to performance. While traditional materials processing segments, like cutting, remained challenged, areas such as cleaning and additive manufacturing showed resilience.
Looking ahead, management pointed to recently imposed tariffs as a key headwind, indicating that these measures are delaying approximately $15 million in shipments for the next quarter. Dr. Gitin explained that these delays are not cancellations but reflect ongoing optimization of the company’s global manufacturing footprint to offset tariff exposure. CFO Tim Mammen added that the company expects to substantially reduce the margin impact of tariffs by the end of the year through supply chain adjustments and selective pricing actions.
Key Insights from Management’s Remarks
IPG Photonics’ management provided detailed context on the business environment, highlighting both stabilization in legacy markets and traction in emerging growth areas. The quarter’s outperformance versus Wall Street revenue expectations was underpinned by strategic wins in medical and advanced applications, while tariff-related delays and higher operating expenses weighed on forward guidance.
Bookings Momentum: Sequential improvement in bookings and a book-to-bill ratio above 1 signaled strengthening demand, particularly in e-mobility in China and medical applications in the U.S. Management emphasized that these gains are beginning to offset weakness in traditional cutting markets.
Medical and Micromachining Growth: The addition of a new urology customer and the launch of a new micromachining product nearly doubled revenue in those areas, with management highlighting the significant long-term growth opportunity in both markets.
Tariff Impact and Supply Chain Response: Recently imposed tariffs are causing shipment delays but not cancellations. Management is leveraging its flexible global manufacturing base to shift production and minimize cost impacts, aiming to resolve most delays by the third quarter.
Product and Application Diversification: The cleanLASER acquisition and partnership with AkzoNobel to apply laser technology to powder coatings are expanding IPG’s addressable markets, targeting applications beyond traditional materials processing.
Operating Expense Increase: Investments in R&D, compensation, and benefits drove operating expenses higher. Management views these as necessary to support strategic initiatives, with expectations that operating leverage will improve as revenue from new programs scales.
Drivers of Future Performance
Management’s outlook for the next quarter remains cautious due to tariff-related disruptions, but the company is focused on mitigating these effects through supply chain adjustments and product mix expansion.
Tariff Mitigation Strategy: Management is optimizing manufacturing locations and supplier sourcing to reduce tariff exposure, aiming to restore margins by the end of the year.
Expansion of Growth Applications: Continued investment in medical, micromachining, and advanced applications is expected to drive future revenue diversification, with new product launches planned for later this year.
Ongoing Macroeconomic Uncertainty: Management acknowledged persistent uncertainty in core industrial end markets, particularly in traditional cutting and welding, and is monitoring recovery trends and inventory normalization closely.
Top Analyst Questions
Ruben Roy (Stifel): Asked about the strength of bookings growth by geography and application; management attributed gains to e-mobility in China, medical in the U.S., and normalization in Japan.
Jim Ricchiuti (Needham & Company): Inquired about the AkzoNobel partnership and medical business timing; Dr. Gitin stated powder coating applications are in early stages, while new medical systems will meaningfully contribute in 2026.
Michael Feniger (Bank of America): Sought clarity on tariff impacts and pricing strategy; management explained cost increases are temporary and mitigated by shifting production and selective pricing.
Scott Graham (Seaport Research Partners): Questioned manufacturing footprint changes and competitive dynamics; management detailed moving production away from tariff-affected regions and emphasized differentiation outside China’s cutting segment.
Keith Housum (Northcoast Research): Asked about the book-to-bill ratio and duration of backlog; CFO Tim Mammen explained medical orders have longer lead times, while most other areas remain short-cycle.
Catalysts in Upcoming Quarters
In coming quarters, the StockStory team will closely monitor (1) the company’s progress in resolving tariff-related shipment delays and restoring margin levels, (2) the continued growth and customer adoption of new medical and micromachining products, and (3) evidence of stabilization or renewed growth in core cutting and welding applications. The effectiveness of supply chain adjustments and execution on strategic partnerships, such as with AkzoNobel, will also be important indicators of future performance.
IPG Photonics currently trades at a forward P/E ratio of 41.2×. In the wake of earnings, is it a buy or sell? Find out in our free research report.
Stocks That Trumped Tariffs in 2018
The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.
While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
